Liquid Biopsy Detects 50+ Cancer Types from Single Blood Draw
Multi-cancer early detection test achieves 99.5% specificity, revolutionizing screening protocols.
1The Technology
A next-generation liquid biopsy test can detect over 50 types of cancer from a single blood draw with 99.5% specificity and an overall sensitivity of 67.3%, according to results from a prospective validation study involving 140,000 participants .
2Multi-Cancer Detection
The test, which analyzes cell-free DNA methylation patterns, can not only detect the presence of cancer but also predict the tissue of origin with 93% accuracy . This is critical for directing follow-up diagnostic workups and avoiding unnecessary invasive procedures.
3Specificity & Sensitivity
Sensitivity varied by cancer stage, ranging from 39% for Stage I to 92% for Stage IV . Notably, the test showed strong performance for cancers that currently lack screening methods, including pancreatic (63%), ovarian (69%), and liver cancer (72%).
4Clinical Deployment
The FDA has granted Breakthrough Device designation, and the test is expected to be available in clinical settings within 12 months. At an estimated cost of $950 per test, health economists project it could be cost-effective as an annual screening for adults over 50 .
- Detects 50+ cancer types from single blood draw
- 99.5% specificity, 67.3% overall sensitivity
- 93% accuracy in predicting tissue of origin
- Strong performance for cancers lacking screening methods
- FDA Breakthrough Device designation granted
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Cancer Screening.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Diagnostics Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
9,210 consumers have expressed interest in this topic. Researchers studying Cancer Screening can see anonymized demand signals.
Liquid Biopsy Detects 50+ Cancer Types from Single Blood Draw
Multi-cancer early detection test achieves 99.5% specificity, revolutionizing screening protocols.
1The Technology
A next-generation liquid biopsy test can detect over 50 types of cancer from a single blood draw with 99.5% specificity and an overall sensitivity of 67.3%, according to results from a prospective validation study involving 140,000 participants .
2Multi-Cancer Detection
The test, which analyzes cell-free DNA methylation patterns, can not only detect the presence of cancer but also predict the tissue of origin with 93% accuracy . This is critical for directing follow-up diagnostic workups and avoiding unnecessary invasive procedures.
3Specificity & Sensitivity
Sensitivity varied by cancer stage, ranging from 39% for Stage I to 92% for Stage IV . Notably, the test showed strong performance for cancers that currently lack screening methods, including pancreatic (63%), ovarian (69%), and liver cancer (72%).
4Clinical Deployment
The FDA has granted Breakthrough Device designation, and the test is expected to be available in clinical settings within 12 months. At an estimated cost of $950 per test, health economists project it could be cost-effective as an annual screening for adults over 50 .
- Detects 50+ cancer types from single blood draw
- 99.5% specificity, 67.3% overall sensitivity
- 93% accuracy in predicting tissue of origin
- Strong performance for cancers lacking screening methods
- FDA Breakthrough Device designation granted
Dive Deeper into the Research
Switch to PhD Mode to explore the underlying papers, knowledge graph connections, pathway analyses, and collaborate with researchers working on Cancer Screening.
In This Article
Related Conditions
Active Clinical Trials
Phase III: Diagnostics Study
Recruiting at 12 sites nationwide
Related Articles
Researcher Interest
9,210 consumers have expressed interest in this topic. Researchers studying Cancer Screening can see anonymized demand signals.